Neuroscience biotech Cerevance launched with mm Series A, including investment from Takeda

Jan 2017 Executive Summary Neuroscience start-up Cerevance Inc. (focused on therapeutics for neurological and psychiatric disorders) was launched with a $36mm Series A round, including a $21.5mm investment from Takeda Pharmaceutical and Lightstone Ventures, which both contributed a member to the new company’s board. Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription View on strategic transactions Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products Learn more Questions? Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com


Link to Full Article: Neuroscience biotech Cerevance launched with mm Series A, including investment from Takeda

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!